---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-021738"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2025-03-07T23:59:59+00:00"
generated_at: "2026-05-25T03:35:34.043012+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adial Pharma receives Nasdaq bid price deficiency notice; compliance deadline Sept 1, 2025

## Summary
- Received Nasdaq notice March 5, 2025 for failing minimum bid price of $1.00 for 30 consecutive business days (Jan 17 - Mar 4, 2025).
- No immediate effect on listing or trading; common stock continues on Nasdaq Capital Market under symbol ADIL.
- Company has until September 1, 2025 (180 days) to regain compliance by achieving $1.00 closing bid for 10 consecutive days.
- If noncompliant by Sept 1, Company may be eligible for additional 180-day period if meets other listing standards.
- Company considering available options, including a reverse stock split, to cure the bid price deficiency.

## SEC filing metadata
- accession: 0001213900-25-021738
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2025-03-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390025021738/0001213900-25-021738-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390025021738/ea0233491-8k_adial.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-021738
- JSON: https://secwatch.observer/filing/0001213900-25-021738.json
- Plain text: https://secwatch.observer/filing/0001213900-25-021738.txt

## Key facts
- Listing & Compliance Notices
  ADIAL PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: March 5, 2025, Adial Pharmaceuticals, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days (January 17, 2025 through March 4, 2025), the Company’s common stock did not maintain a minimum closing bid price of $1.00 (“Minimum Bid Price Requirement”) per share as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on The Na
  evidence_url: https://www.sec.gov/Archives/edgar/data/1513525/000121390025021738/0001213900-25-021738-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.